Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 6/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 3/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | PTGES2 | Q9H7Z7 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.33 |
| ▸ | BAD | Q92934 | 1/20 | 0.33 |
| ▸ | STAT3 | P40763 | 1/20 | 0.33 |
| ▸ | DPP4 | P27487 | 1/20 | 0.33 |
| ▸ | METAP2 | P50579 | 1/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL3920726 | 0.80 | CES1 (0.41) | CES1ALDH1A1LMNANPSR1POLB | |
| SCHEMBL22802458 | 0.80 | HTR2A (0.40) | CES1ALDH1A1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL3919084 | 0.79 | ALDH1A1 (0.42) | CES1ALDH1A1LMNANPSR1POLB | |
| SCHEMBL20112700 | 0.69 | CES1 (0.52) | CES1ALDH1A1LMNABCL2L1BAD | |
| SCHEMBL599446 | 0.69 | CES1 (0.43) | CES1ALDH1A1LMNABCL2L1BAD | |
| SCHEMBL4091751 | 0.69 | TDP2 (0.39) | ALDH1A1LMNANPSR1KDM4EGAA | |
| SCHEMBL16527054 | 0.68 | CES1 (0.40) | CES1LMNABCL2L1BADSTAT3 | |
| SCHEMBL13950606 | 0.68 | CES1 (0.39) | CES1ALDH1A1LMNAKDM4EGAA | |
| SCHEMBL30727415 | 0.68 | BCL2L1 (0.47) | CES1ALDH1A1LMNANPSR1SMN1; SMN2 | |
| SCHEMBL3358410 | 0.68 | BCL2L1 (0.47) | CES1ALDH1A1LMNANPSR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7534787-B2 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-19 | — | — | US | disclosed |
| US-20090099159-A1 | Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-16 | — | — | US | disclosed |
| US-7393843-B2 | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-01 | — | — | US | disclosed |
| US-20080139541-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BORNEMANN KLAUS | 2008-06-12 | — | — | US | disclosed |
| US-7375220-B2 | Method of treating diseases and conditions associated with an altered level of amyloid β peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2008-05-20 | — | — | US | disclosed |
| EP-1750719-A2 | TREATMENT OF DISEASES ASSOCIATED WITH ALTERED LEVEL OF AMYLOID BETA PEPTIDES | Boehringer Ingelheim International GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-20060040928-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM VETMEDICA GMBH (DE) | 2006-02-23 | — | — | US | disclosed |
| US-20050277635-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-12-15 | — | — | US | disclosed |
| WO-2005110422-A2 | TREATMENT OF DISEASES ASSOCIATED WITH ALTERED LEVEL OF AMYLOID BETA PEPTIDES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060040928-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | CES1 69/4885ALDH1A1 1191/4885LMNA 35/4885 |
| US-20090099159-A1 | Method of Treating Diseases and Conditions Associated with an Altered Level of Amyloid Beta Peptides and New Enolcarboxamide Compounds | APP, BACE1, PSEN1 | CES1 69/4885ALDH1A1 1191/4885LMNA 35/4885 |
| US-20050277635-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | CES1 69/4885ALDH1A1 1191/4885LMNA 35/4885 |
| US-20080139541-A1 | Method of treating diseases and conditions associated with an altered level of amyloid beta peptides and new enolcarboxamide compounds | APP, BACE1, PSEN1 | CES1 73/4885ALDH1A1 1177/4885LMNA 35/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.